argenx

ARGENX SE - ADR

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

biotech lab

Analyst Color

Biotech

News

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

ARGX

KYTX

RNAC

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.

With Trials In Motion, Cash To 2027, Can Kyverna&#39;s Next Data Drop Turn The Stock Around?

Kaunas,,Lithuania,-,March,23:,Caterpillar,Heavy,Duty,Equipment,Vehicle

Markets

AFMD

NXRT

This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Indianapolis,-,Circa,November,2021:,Eli,Lilly,And,Company,World

Earnings

Equities

Large Cap

AFRM

BNTX

DASH

MMYT

REGN

SMMT

VRTX

The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

argenx SE

Press Releases

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

argenx to Present at BofA Securities 2025 Health Care Conference

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

argenx Announces Results of Annual General Meeting of Shareholders

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Comments

argenx

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell